What Medications Are Used to Treat Binge Eating?

Why It Matters

The limited pharmacologic options make Vyvanse a critical tool for clinicians, while the proven efficacy of CBT underscores the need for integrated, multidisciplinary care. Understanding both approaches helps patients achieve lasting symptom control and reduces long‑term health risks.

Key Takeaways

• Vyvanse is the only FDA‑approved drug for binge‑eating disorder.
• CBT reduces binge episodes but doesn't guarantee weight loss.
• Off‑label weight‑loss drugs like semaglutide are sometimes used.
• Treatment typically lasts about three months; combined approaches boost success.
• Vyvanse patients must avoid amphetamine hypersensitivity and recent MAOI use.

Pulse Analysis

Binge‑eating disorder (BED) is the most common eating disorder in the United States, affecting roughly 2‑3 % of adults and driving higher rates of diabetes, heart disease, and depression. The disorder’s hallmark is recurrent, uncontrolled consumption of large food quantities, often accompanied by profound distress. In 2015 the FDA granted approval to Vyvanse (lisdexamfetamine) as the first and only medication specifically indicated for BED, leveraging its stimulant action to curb impulsive eating patterns. Prescribers must screen for amphetamine hypersensitivity, recent monoamine oxidase inhibitor use, and cardiovascular risk before initiating therapy, given the drug’s potential for misuse and side‑effects such as insomnia, anxiety, and elevated blood pressure.

While medication addresses neurochemical drivers, psychotherapy tackles the cognitive and emotional triggers that sustain binge cycles. Cognitive‑behavioral therapy (CBT) remains the gold‑standard, typically delivered in weekly sessions over a three‑month horizon, and has demonstrated robust reductions in binge frequency. However, CBT alone often falls short on weight‑loss goals, prompting clinicians to layer behavioral weight‑loss counseling or interpersonal therapy. The synergy of pharmacologic and behavioral interventions is increasingly recognized as essential; patients who receive both report higher remission rates and better quality‑of‑life metrics than those treated with a single modality.

Off‑label use of weight‑loss agents—particularly GLP‑1 receptor agonists such as semaglutide (Ozempic) and liraglutide (Victoza)—is gaining traction for BED patients with obesity, capitalizing on appetite‑suppressing effects that complement Vyvanse’s impulse‑control benefits. Emerging research suggests that combining these agents with CBT may extend symptom relief beyond the medication‑on period, though long‑term safety data remain limited. As insurers and providers navigate coverage decisions, the evolving therapeutic landscape underscores the importance of personalized treatment plans that balance efficacy, safety, and patient preference, positioning BED as a focal point for future mental‑health and metabolic‑care integration.